By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – French molecular diagnostics company IntegraGen has been awarded a €1.6 million ($2.4 million) interest-free loan from the French government to develop cancer biomarker tools, the company said Wednesday.

IntegraGen will use the loan from OSEO (the French state innovation agency) to partner with the French National Institute of Health and Medical Research (INSERM) to develop biomarker panels for personalized medicine and management of liver and colon cancer patients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.